ArticleJournal of lipid research2013
Phosphatidylglycerol provides short-term prophylaxis against respiratory syncytial virus infection.
Article in Journal of lipid research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 51 citations in OpenAlex.
- Valproic acid remodels phosphatidylglycerol homeostasis and epithelial-macrophage crosstalk in inflammatory signaling.iScience · 2026Article
- Therapeutic benefits of glycerol in dry eye disease.Frontiers in medicine · 2024Article
- Article
- The anti-inflammatory and antiviral properties of anionic pulmonary surfactant phospholipids.Immunological reviews · 2023Review
- Phosphatidylglycerol to Treat Chronic Skin Wounds in Diabetes.Pharmaceutics · 2023Review
- Dioleoylphosphatidylglycerol Inhibits Heat Shock Protein B4 (HSPB4)-Induced Inflammatory Pathways In Vitro.International journal of molecular sciences · 2023Article
- Anionic Pulmonary Surfactant Lipid Treatment Inhibits Rhinovirus A Infection of the Human Airway Epithelium.Viruses · 2023Article
- Anti-inflammatory and anti-viral actions of anionic pulmonary surfactant phospholipids.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2022Review
- Lipid biophysics and/or soft matter-inspired approach for controlling enveloped virus infectivity.Journal of the Royal Society, Interface · 2022Article
- Integrative genetics-metabolomics analysis of infant bronchiolitis-childhood asthma link: A multicenter prospective study.Frontiers in immunology · 2022Article
- Insights Gained Into the Treatment of COVID19 by Pulmonary Surfactant and Its Components.Frontiers in immunology · 2022Review
- Updated Perspectives on Keratinocytes and Psoriasis: Keratinocytes are More Than Innocent Bystanders.Psoriasis (Auckland, N.Z.) · 2022Review
- Potential Therapeutic Applications of Pulmonary Surfactant Lipids in the Host Defence Against Respiratory Viral Infections.Frontiers in immunology · 2021Review
- Phosphatidylglycerol and surfactant: A potential treatment for COVID-19?Medical hypotheses · 2020Article
- Lipid-Protein and Protein-Protein Interactions in the Pulmonary Surfactant System and Their Role in Lung Homeostasis.International journal of molecular sciences · 2020Review
- Pathogen-Associated Molecular Pattern-Induced TLR2 and TLR4 Activation Increases Keratinocyte Production of Inflammatory Mediators and is Inhibited by Phosphatidylglycerol.Molecular pharmacology · 2020Article
- Dioleoylphosphatidylglycerol Accelerates Corneal Epithelial Wound Healing.Investigative ophthalmology & visual science · 2020Article
- Pulmonary surfactant lipids inhibit infections with the pandemic H1N1 influenza virus in several animal models.The Journal of biological chemistry · 2020Article
- Intracellular cholesterol trafficking is dependent upon NPC2 interaction with lysobisphosphatidic acid.eLife · 2019Article
- Phosphatidylglycerol Inhibits Toll-Like Receptor-Mediated Inflammation by Danger-Associated Molecular Patterns.The Journal of investigative dermatology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
Respiratory syncytial virus (RSV) causes respiratory tract infections in young children, and significant morbidity and mortality in the elderly, immunosuppressed, and immunocompromised patients and in patients with chronic lung diseases. Recently, we reported that the pulmonary surfactant phospholipid palmitoyl-oleoyl-phosphatidylglycerol (POPG) inhibited RSV infection in vitro and in vivo by blocking viral attachment to epithelial cells. Simultaneous application of POPG along with an RSV challenge to mice markedly attenuated infection and associated inflammatory responses. Based on these findings, we expanded our studies to determine whether POPG is effective for prophylaxis and postinfection treatment for RSV infection. In vitro application of POPG at concentrations of 0.2-1.0 mg/ml at 24 h after RSV infection of HEp-2 cells suppressed interleukin-8 production up to 80% and reduced viral plaque formation by 2-6 log units. In vivo, the turnover of POPG in mice is relatively rapid, making postinfection application impractical. Intranasal administration of POPG (0.8-3.0 mg), 45 min before RSV inoculation in mice reduced viral infection by 1 log unit, suppressed inflammatory cell appearance in the lung, and suppressed virus-elicited interferon-γ production. These findings demonstrate that POPG is effective for short-term protection of mice against subsequent RSV infection and that it has potential for application in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.